Britt Meelby Jensen
President and Chief Executive Officer (CEO)
Britt Meelby Jensen (Danish, born 1973) joined Zealand as CEO in January 2015. Before joining Zealand, she headed the world leading Agilent-owned Danish diagnostics company, Dako, as the company’s CEO.
Britt has extensive experience from a range of managerial positions within the life science industry, including 11 years of international experience from Novo Nordisk. In Novo Nordisk, she has held the position as Global Marketing Director for Diabetes Lifecycle Management, Nordic Marketing Manager for Diabetes and since 2008 she was Corporate Vice President for Global Marketing, Market Access and Commercial Excellence.
Previously, Britt has worked for McKinsey and Company and within the EU Institutions in Brussels. She has a M.Sc. in International Marketing Management from Copenhagen Business School, Denmark and an MBA from Solvay Business School in Brussels, Belgium.
Executive Vice President and Chief Scientific Officer (CSO)
Dr. Torsten Hoffmann (German, born 1967) joined Zealand as CSO in October 2013 from Roche, where he spent 16 years in several managerial positions, including as Head of Discovery Chemistry in the Pharma Research division of the company’s headquarters in Basel.
At the department of Discovery Chemistry at Roche, which he led for eight years, more than 280 peer reviewed publications and 540 patent applications were documented. Torsten is an inventor of netupitant, a neurokinin 1 receptor antagonist which was FDA approved as Akynzeo® in 2014. Additionally, Torsten is the author of more than 80 research publications, published conference reports and patent applications.
Torsten studied chemistry at the Heinrich-Heine University in Düsseldorf and received his doctorate at the Eidgenössische Technische Hochschule in Zürich. Following this he held a position as post-doc at the Scripps Research Institute in California. He has received several prizes and awards and has been listed in Marquis’ “Who’s Who in the World” and “Who’s Who in Medicine and Healthcare” since 2007.
Torsten serves on the Advisory Boards of Elsevier Life Sciences, Elsevier SA, Amsterdam, the Department of Chemistry, University of Basel, the Peptide Therapeutics Foundation, US, the Bolder Peptide Symposium, US, and the Center for Biopharmaceuticals, University of Copenhagen.
Senior Vice President and Chief Financial Officer (CFO)
Mats Blom (Swedish, born 1965) joined Zealand as CFO in March 2010. Prior to joining Zealand, Mats served as Chief Financial Officer at Swedish Orphan International a leading European orphan drug company acquired by BioVitrum of Sweden in 2009 (now Sobi Pharmaceuticals).
Mats has extensive managerial experience and he has held CFO positions at Active Biotech and Anoto both publicly listed on Nasdaq Stockholm stock exchange Previously, Mats has worked several years as a management consultant at Gemini Consulting and at Ernst & Young’s Transaction Services division.
Mats hold a BA in Business Administration and Economics from the University of Lund followed by an MBA from IESE University of Navarra, Barcelona.
Mats is Chairman of the board for Medical Need AB.
Senior Vice President and Chief Operating Officer (COO)
Agneta Svedberg (Swedish, born 1963) joined Zealand in February 2013 from Cantargia AB, a Swedish biotech company, where she held the position as CEO.
Agneta has more than 20 years of experience in drug development from different leadership functions in both biotech and big pharma companies. This includes more than ten years with Genmab A/S in Copenhagen, where she was part of the Senior Management team as Global Head of Clinical Development and Copenhagen site Manager with responsibility for 200 people. Before joining Genmab A/S, Agneta was Head of Clinical Development (Europe) at Oxigene Europe AB and prior to this held managerial positions at Pharmacia & Upjohn AB in Sweden.
Agneta holds a M.Sc. in Radiation Physics from Lund University and an Executive MBA from Lund University School of Economics and Management, Sweden.